We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Brand manufacturer Mayne Pharma and Warner Chilcott, U.S. marketer of Mayne’s acne drug Doryx, have moved to settle class action claims with third party purchasers that allege the two companies inappropriately delayed generic competition on the product. Read More
Canadian pharmaceutical company Duchesnay has filed a lawsuit against generic manufacturer Actavis over its challenge to Duchesnay’s morning sickness drug Diclegis. Read More
A federal appellate judge has ordered brand firm Endo and generics manufacturer Mylan to continue negotiating a court-mandated settlement that will allow Mylan to market a generic version of Endo’s migraine drug Frova. Read More
Baxter is voluntarily recalling four lots of intravenous solutions in response to customer complaints of plastic and fiber particles in the product, its fourth recall this year related to particulates. Read More
More than four years after Congress allowed biosimilars, Sandoz said yesterday that the FDA had accepted its application for a biosimilar of Amgen’s Neupogen, a milestone in the race to develop the highly anticipated biological products. Read More
The British healthcare cost evaluation agency has recommended coverage of Astellas Pharma’s prostate cancer drug Xtandi and Bristol-Myers Squibb’s melanoma treatment Yervoy, noting that the therapies provide sufficient gains in overall survival of patients who were treated for the cancers. Read More